help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mechanick, J. I.
Right arrow Articles by Autelitano, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mechanick, J. I.
Right arrow Articles by Autelitano, D. J.

Endocrinology, Vol 131, 518-525, Copyright © 1992 by Endocrine Society


ARTICLES

Proopiomelanocortin gene expression in a distinct population of rat spleen and lung leukocytes

JI Mechanick, N Levin, JL Roberts and DJ Autelitano
Dr. Arthur M. Fishberg Research Center for Neurobiology, The Mount Sinai School of Medicine, New York, New York 10029.

Existence of proopiomelanocortin (POMC) messenger RNA (mRNA) and related peptides in extrapituitary sites has been demonstrated in immune cells, although the particular type of immune cell has been the source of considerable debate. Specifically, double labeling studies have shown that POMC peptide expressing cells in the spleen represent a subpopulation of red pulp macrophages, while splenic lymphocyte areas are POMC negative. In addition, it has also been reported that peripheral blood leukocytes express the POMC gene. Using a sensitive solution hybridization technique with a POMC exon-1 RNA probe, we detected 70 +/- 20 fg and 65 +/- 5 fg POMC mRNA per microgram total RNA in whole spleen and lung, respectively, approximately 20,000-fold lower concentrations than found in the neurointermediate lobe of the pituitary. The presence of nuclease protected full length exon-1 bands, rather than the 5' truncated POMC RNAs seen in many nonpituitary tissues, indicates transcription initiation at the normal pituitary POMC promoter site in lung and spleen. In order to localize POMC gene expression in these tissues we employed an in situ hybridization method. There was an intense signal in a small population of large mononuclear cells scattered throughout the splenic red pulp and lung parenchyma. In the lung, these cells were concentrated in the periarteriolar zone in a manner suggestive of migration from the intravascular lumen. These cells had a histomorphology suggestive of monocyte-macrophages. POMC mRNA was undetectable in the splenic white pulp and bronchus-associated lymphoid tissue, indicating an absence of POMC gene expression in splenic and lung lymphocytes. Immunocytochemical studies suggested that POMC-positive cells made up a subpopulation of cells expressing the rat monocyte-macrophage markers ED1 and ED2. Similarly, the distribution of Jenner-Giemsa stained monocyte-macrophages appeared to overlap with POMC positive cells. Studies with anti-rat beta-endorphin antisera revealed scattered cells in the splenic red pulp and lung parenchyma, suggesting that the POMC mRNA is translated in these cells. In summary, POMC mRNA is expressed in a small population of monocyte-macrophage-like cells in lung and spleen but not in lymphocytes in these tissues.


This article has been cited by other articles:


Home page
JPEN J Parenter Enteral NutrHome page
J. I. Mechanick
Metabolic Mechanisms of Stress Hyperglycemia
JPEN J Parenter Enteral Nutr, March 1, 2006; 30(2): 157 - 163.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
S. A. Mousa, M. Shakibaei, N. Sitte, M. Schafer, and C. Stein
Subcellular Pathways of {beta}-Endorphin Synthesis, Processing, and Release from Immunocytes in Inflammatory Pain
Endocrinology, March 1, 2004; 145(3): 1331 - 1341.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
S. J. Getting, G. H. Allcock, R. Flower, and M. Perretti
Natural and synthetic agonists of the melanocortin receptor type 3 possess anti-inflammatory properties
J. Leukoc. Biol., January 1, 2001; 69(1): 98 - 104.
[Abstract] [Full Text]


Home page
Physiol. Rev.Home page
A. Slominski, J. Wortsman, T. Luger, R. Paus, and S. Solomon
Corticotropin Releasing Hormone and Proopiomelanocortin Involvement in the Cutaneous Response to Stress
Physiol Rev, July 1, 2000; 80(3): 979 - 1020.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
C. R. Vines and D. A. Weigent
Identification of SP3 as a Negative Regulatory Transcription Factor in the Monocyte Expression of Growth Hormone
Endocrinology, March 1, 2000; 141(3): 938 - 946.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. J. Getting, L. Gibbs, A. J. L. Clark, R. J Flower, and M. Perretti
POMC Gene-Derived Peptides Activate Melanocortin Type 3 Receptor on Murine Macrophages, Suppress Cytokine Release, and Inhibit Neutrophil Migration in Acute Experimental Inflammation
J. Immunol., June 15, 1999; 162(12): 7446 - 7453.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1992 by The Endocrine Society